PULMORNA

Serial Number 98675394
686

Registration Progress

Application Filed
Jul 31, 2024
Under Examination
Approved for Publication
Jun 3, 2025
Published for Opposition
Jun 3, 2025
Registered

Basic Information

Serial Number
98675394
Filing Date
July 31, 2024
Published for Opposition
June 3, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
686
Status Date
Jun 3, 2025
Application
Pending
Classes
042

Rights Holder

Mochida Pharmaceutical Co., Ltd.

29
Address
1-7, Yotsuya Shinjuku-ku
Tokyo 160-8515
JP

Ownership History

Mochida Pharmaceutical Co., Ltd.

Original Applicant
29
Tokyo JP

Mochida Pharmaceutical Co., Ltd.

Owner at Publication
29
Tokyo JP

Legal Representation

Attorney
Mary Margaret L. O'Donnell

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

19 events
Date Code Type Description
Jun 3, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 3, 2025 PUBO A PUBLISHED FOR OPPOSITION
May 28, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 30, 2025 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 30, 2025 GNEA F EXAMINERS AMENDMENT E-MAILED
Apr 30, 2025 XAEC I EXAMINER'S AMENDMENT ENTERED
Apr 30, 2025 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 30, 2025 CNEA R EXAMINERS AMENDMENT -WRITTEN
Apr 15, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 15, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 15, 2025 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 7, 2025 CNSL R SUSPENSION LETTER WRITTEN
Feb 7, 2025 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 7, 2025 GNSL F LETTER OF SUSPENSION E-MAILED
Feb 6, 2025 DOCK D ASSIGNED TO EXAMINER
Jan 16, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 15, 2024 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED
Oct 15, 2024 TAEA I TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Jul 31, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 042
Research and development of vaccines, medicines, and pharmaceutical preparations; Scientific research and development; Research and development in the field of cell-free processing; Research and development in the pharmaceutical, medical, biotechnology, bioengineering, biochemical and biomedical fields; Research and development in the field of synthetic and biological formulations for scientific, medical, pharmaceutical, veterinary, chemical, energy, industrial, and manufacturing use

Additional Information

Pseudo Mark
PULMO RNA; PULMO RIBONUCLEIC ACID

Classification

International Classes
042